Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer MRD testing helps clinicians track a patient's risk ...

(RTTNews) - Labcorp (LH) Wednesday has announced a significant expansion of its precision oncology offerings with two advanced diagnostic solutions to improve cancer detection and treatment decisions.

BURLINGTON, N.C. - Labcorp (NYSE:LH) announced Tuesday it has expanded its molecular residual disease (MRD) testing portfolio to help clinicians detect cancer recurrence earlier than traditional ...

FIT outperformed cfDNA in detecting advanced precancerous colorectal lesions, showing higher sensitivity and specificity. Blood-based tests offer easier implementation and potentially higher adherence ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...